Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK investigational FluNG vaccine GSK2186877A, aged lot · 1 trial · 1 indication
Titers are presented as Geometric Mean Titers. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane.
| Arm | Type | Description |
|---|---|---|
| FluNG Aged Group | EXPERIMENTAL | Subjects receiving 1 dose of an aged lot of FLU NG vaccine (GSK2186877A). |
| FluNG Fresh Group | EXPERIMENTAL | Subjects receiving 1 dose of a fresh lot of FLU NG vaccine (GSK2186877A). |
| Name | Type | Description |
|---|---|---|
| GSK investigational FluNG vaccine GSK2186877A, aged lot | BIOLOGICAL | Single dose, intramuscular injection |
| GSK investigational FluNG vaccine GSK2186877A, fresh lot | BIOLOGICAL | Single dose, intramuscular injection |
Inclusion Criteria: * Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study. Specific attention should be given to the compliance potential of subjects with suspected or known drug or alcohol abuse. * A man or woma...
Top 6 of 9 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sinovac Biotech Ltd. | SVA | 1 | PHASE3 | Quadrivalent influenza vaccine (split virion), inactivated |
| Moderna, Inc. | MRNA | 1 | PHASE3 | mRNA-1018-H5 |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | CDTX | 1 | PHASE3 | CD388 |
| Traws Pharma, Inc. | TRAW | 2 | PHASE2 | TRX-100 |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD4117, AZD5315 |
| GSK plc Sponsored ADR | GSK | 1 | PHASE1 | Flu/COVID-19 mRNA combination vaccine |
GSK2186877A is an investigational influenza vaccine developed by GSK plc for the prevention of influenza in elderly adults aged 65 years and older. It is designed to induce an immune response against influenza virus in this older population.
GSK2186877A is being developed by GSK plc, which trades on the New York Stock Exchange under the ticker GSK. GSK is the sponsor of the clinical program evaluating this investigational influenza vaccine.
GSK2186877A has been evaluated in a Phase 3 clinical trial. The completed Phase 3 study, NCT00938392, assessed the immunogenicity and safety of this investigational influenza vaccine in elderly participants. The vaccine remains investigational and is not approved for use.
GSK2186877A was studied in a single Phase 3 trial, NCT00938392, titled "Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine for the Elderly." The trial enrolled 726 participants aged 65 years and older in Estonia and Slovakia and has been completed.
The Phase 3 trial NCT00938392 was a randomized, double-blind, controlled study evaluating the immunogenicity and safety of GSK2186877A in healthy volunteers aged 65 years and older. It enrolled 726 participants across sites in Estonia and Slovakia and has been completed.